DENTSPLY SIRONA Inc. XRAY reported first-quarter 2024 adjusted earnings per share (EPS) of 42 cents, which aligns with the Zacks Consensus Estimate. The bottom line improved 7.9% on a year-over-year basis. On a GAAP basis, the company reported an EPS of 9 cents against the loss of 9 cents per share reported in the year-ago quarter. Revenues Revenues in the reported quarter totaled $953 million, which missed the Zacks Consensus Estimate by 1.8%. The top line declined 2.6% year over year and 1.9% on an organic basis. Business Details The company reports quarterly results under four segments — Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. While the Connected Technology Solutions segment consists of equipment, instruments and CAD/CAM business, the Orthodontic and Implant Solutions segment includes the implant systems and aligner solutions. These businesses were formerly part of the Technologies and Equipment segment. The Essential Dental Solutions unit includes endodontic, restorative and preventive consumables businesses, which were part of the former Consumables segment. The Wellspect Healthcare segment includes the urology catheters business, a former part of Technologies & Equipment, and other healthcare-related consumable businesses, previously under the Consumables segment. Connected Technology Solutions Revenues in this segment totaled $247 million, down 6.9% year over year and 5.7% on an organic basis. Orthodontic and Implant Solutions Sales in this segment amounted to $271 million, up 4.4% year over year. On an organic basis, net sales improved 5.6%. Essential Dental Solutions Sales in this segment amounted to $364 million, down 5.9% year over year. On an organic basis, net sales declined 5.5%. Wellspect Healthcare Sales in this segment amounted to $71 million, up 5.4% year over year. On an organic basis, net sales improved 4.8%. Revenues by Geography In the United States, revenues increased 1.4% year over year organically to $356 million. Rest of World revenues decreased 0.1% organically to $221 million on a year-over-year basis. Revenues in Europe declined 5.8% to $376 million organically during the same time frame. Margin Analysis Gross profit in the reported quarter was $506 million, down 2.5% on a year-over-year basis. The gross margin came in at 53.1%, flat year over year. Selling, general and administrative expenses totaled $415 million, down 0.2% from the year-ago quarter’s level. Research and development expenses amounted to $42 million, down 8.7% year over year. Operating income totaled $42 million against the operating loss of $2 million in the year-ago period. Financial Condition DENTSPLY SIRONA exited the first quarter of 2024 with cash and cash equivalents of $291 million compared with $334 million at the end of the last reported quarter. The cumulative net cash provided by operating activities totaled $25 million against net cash used in operating activities of $21 million in the year-ago period. 2024 Guidance Maintained DENTSPLY SIRONA reiterated its guidance for 2024 earnings and revenues. The company expects sales in the band of $3.91-$3.97 billion, implying flat to 1.5% growth organically. The Zacks Consensus Estimate for the same is pegged at $3.99 billion. XRAY expects adjusted EPS in the band of $2.00-$2.10. The Zacks Consensus Estimate for the same is pinned at $2.05. Our Take XRAY’s first-quarter adjusted earnings are in line while revenues missed the Zacks Consensus Estimate. Recovery of demand in China is likely to be a key driver of the top line going forward. Moreover, strong demand for aligners and CAD/CAM in the U.S. market will support revenue growth in the future. DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise DENTSPLY SIRONA Inc. price-consensus-eps-surprise-chart | DENTSPLY SIRONA Inc. Quote Zacks Rank and Stocks to Consider Currently, DENTSPLY SIRONA has a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. ALGN, Ecolab ECL and Boston Scientific Corporation BSX. Align Technology, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2024 adjusted EPS of $2.14, beating the Zacks Consensus Estimate by 8.1%. Revenues of $997.4 million outpaced the consensus mark by 2.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Align Technology has a long-term estimated growth rate of 6.9%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 5.9%. Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.7%. Ecolab’s shares have rallied 33.8% against the industry’s 9.3% decline in the past year. Boston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, beating the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. It currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 12.5%. BSX’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 7.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX):Free Stock Analysis Report Ecolab Inc. (ECL):Free Stock Analysis Report Align Technology, Inc. (ALGN):Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...